Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Portfolio Pulse from
Syndax Pharmaceuticals' Revumenib shows promise in treating relapsed/refractory mNPM1 AML, meeting the primary endpoint in a pivotal phase 2 study. An sNDA is expected in the first half of 2025, with a PDUFA action date set for December 26, 2024, for FDA approval consideration for KMT2Ar Acute leukemia patients.
November 12, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals' Revumenib met the primary endpoint in a phase 2 study for mNPM1 AML, creating a potential buy opportunity after a stock fall. An sNDA is expected in 2025, with an FDA decision for KMT2Ar Acute leukemia by December 2024.
The successful phase 2 study results for Revumenib in treating mNPM1 AML patients are significant, as they meet the primary endpoint with statistical significance. This positive outcome, along with the upcoming FDA decision for KMT2Ar Acute leukemia, suggests potential future revenue growth. The recent stock price fall presents a buying opportunity for investors, anticipating future gains from these developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100